Unapproved marketed drug 4 - Avadel Pharmaceuticals

Drug Profile

Unapproved marketed drug 4 - Avadel Pharmaceuticals

Alternative Names: UMD 4 - Avadel Pharmaceuticals; UMD#4 - Avadel Pharmaceuticals; Unapproved marketed drug#4 - Avadel Pharmaceuticals; Undisclosed drug#4 - Avadel Pharmaceuticals

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Eclat Pharmaceuticals
  • Developer Avadel Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Unspecified

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 11 Sep 2015 Clinical trials in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top